Report Description Table of Contents How Are Precision Immunotherapies, Advancing Clinical Pipelines, and Specialized Neuromuscular Care Transforming the Global Inclusion Body Myositis Market? – (Updated On: 28th-Oct-2026) Inclusion Body Myositis (IBM) is a rare, progressive muscle disease that primarily affects adults over 50 years of age, causing gradual muscle weakness, difficulty walking, reduced hand strength, and swallowing complications that require long-term medical management. According to Strategic Market Research, the global Inclusion Body Myositis Market was valued at USD 450.23 million in 2025 and is projected to reach USD 649.13 million by 2032, expanding at a CAGR of 5.4% during 2026–2032. Demand spans neurological consultations, muscle biopsies, diagnostic testing, physical rehabilitation, swallowing interventions, and supportive therapies. The development of targeted medicines also represents a potential future revenue opportunity as pharmaceutical research advances toward treatments capable of slowing disease progression. Inclusion Body Myositis (IBM) is a rare muscle disease that mainly affects older adults. A 2025 medical review reported approximately 46 patients per million people, rising to 139 per million among people over 50 years of age. In the United States, a 2025 study published in Neurology estimated approximately 8,800 diagnosed patients, based on a prevalence rate of 26.45 per million. The study also found that 71% of patients were aged 65 or older at diagnosis, while patients typically experienced symptoms for 4.4 years before receiving a diagnosis. These findings highlight opportunities for earlier disease detection, specialist consultations, and long-term IBM treatment services. IBM also creates substantial long-term treatment needs. The 2025 U.S. study, involving 2,435 patients, found that 23% experienced mobility-related problems, 16% had falls, and 15% had swallowing difficulties before diagnosis. Additionally, 30% visited an emergency department in the year before diagnosis, compared with 17% of people without IBM. These complications support demand for neurological consultations, physiotherapy, walking aids, swallowing therapy, and ongoing patient care. Which Segments Are Leading the Inclusion Body Myositis Market, and Where Are the Fastest-Expanding Opportunities Emerging? By Treatment Type: Supportive Care Leads as Investigational Therapies Advance Leading Segment – Supportive Care Supportive Care held the largest share of the global Inclusion Body Myositis Market, accounting for 35% of the total market, equivalent to USD 157.58 million in 2025, and is projected to expand at a CAGR of 4.55% during 2026–2032. Supportive care remains the primary treatment approach for inclusion body myositis, as conventional medications and immunosuppressants, including corticosteroids, have limited effectiveness in controlling disease progression. Physical therapy, occupational therapy, mobility assistance, and swallowing rehabilitation play essential roles in preserving muscle function, independence, and quality of life. Fastest-Growing Segment – Investigational Therapies Investigational therapies accounted for 10% of the global Inclusion Body Myositis Market, valued at USD 45.02 million in 2025, and are projected to record the fastest CAGR of 12.00% during 2026–2032. Investigational treatments represent a critical advancement toward disease-modifying interventions, particularly as inclusion body myositis responds poorly to conventional corticosteroids and immunosuppressive therapies. Clinical research increasingly focuses on addressing muscle degeneration, abnormal protein accumulation, and immune-mediated damage, creating opportunities for innovative treatments that preserve muscle function and slow disease progression. By Diagnosis: Muscle Biopsy Leads as MRI Use Expands Leading Segment – Muscle Biopsy Muscle biopsy accounted for 38% of the Inclusion Body Myositis Market’s diagnostic revenue, equivalent to USD 171.09 million in 2025, and is projected to grow at a CAGR of 4.68% during 2026–2032. Recognized as the gold standard for confirming Inclusion Body Myositis (IBM), muscle biopsy enables clinicians to identify characteristic muscle tissue abnormalities, distinguish IBM from other inflammatory myopathies, and establish diagnostic certainty. Its clinical significance also extends to determining patient eligibility for therapeutic trials and supporting treatment decisions. Fastest-Growing Segment – MRI Magnetic Resonance Imaging (MRI) accounted for 14% of the diagnostic segment in the global Inclusion Body Myositis (IBM) Market, valued at USD 63.03 million in 2025, and is projected to expand at the fastest CAGR of 7.20% during 2026–2032. MRI plays an increasingly important role in non-invasive muscle assessment, enabling clinicians to identify characteristic patterns of muscle involvement, evaluate disease progression, and differentiate IBM from other inflammatory myopathies. Its ability to support accurate clinical evaluation and longitudinal monitoring strengthens its role in IBM diagnosis and management. By Patient Age Group: Older Adults Lead Care Expenditure and Expansion Leading and Fastest-Growing Segment – 65 Years and Above Patients aged 65 years and above accounted for the largest share of 55%, equivalent to USD 247.63 million in 2025, and are projected to register the fastest CAGR of 5.50% during 2026–2032. Inclusion Body Myositis is a progressive muscle disorder predominantly affecting older adults, with age-related muscle degeneration, declining mobility, and progressive muscle weakness contributing to greater clinical intervention, long-term disease management, rehabilitation services, and supportive care requirements among elderly patients. By Route of Administration: Intravenous Care Leads as Subcutaneous Options Gain Attention Leading Segment – Intravenous Administration Intravenous administration dominated the global Inclusion Body Myositis Market, accounting for 50% of the market, equivalent to USD 225.12 million in 2025, and is projected to grow at a CAGR of 5.10% during 2026–2032. Intravenous immunoglobulin (IVIg) remains a supportive treatment option for sporadic inclusion body myositis (s-IBM), offering potential short-term improvements in swallowing difficulties and selected muscle functions. Although its therapeutic benefits are generally temporary and non-curative, IVIg continues to support symptom management in carefully selected patients requiring specialized clinical care. Fastest-Growing Segment – Subcutaneous Administration Subcutaneous administration accounted for 15% of the global Inclusion Body Myositis Market, valued at USD 67.53 million in 2025, and is projected to register the fastest CAGR of 9.00% during 2026–2032. Subcutaneous immunoglobulin (SCIg) is gaining clinical attention as an alternative off-label treatment option for IBM patients, particularly those experiencing inadequate responses to corticosteroids or conventional immunosuppressive therapies. Its potential for home-based administration, flexible dosing schedules, and reduced dependence on hospital-based infusions supports increasing clinical interest in long-term IBM symptom management. By End User: Hospitals Lead as Specialty Neuromuscular Clinics Expand Leading Segment – Hospitals Hospitals accounted for the largest 44% share of the global Inclusion Body Myositis Market, equivalent to USD 198.10 million in 2025, and are projected to expand at a CAGR of 4.47% during 2026–2032. Hospitals and specialized medical centers serve as primary facilities for IBM diagnosis, multidisciplinary treatment, and long-term disease management. Access to neuromuscular specialists, muscle biopsies, rehabilitation services, and supportive therapies strengthens their central role in managing progressive muscle weakness, swallowing difficulties, and mobility limitations associated with Inclusion Body Myositis. Fastest-Growing Segment – Specialty Clinics Specialty clinics accounted for 28% of the global Inclusion Body Myositis (IBM) Market, equivalent to USD 126.06 million in 2025, and are projected to record the fastest CAGR of 6.50% during 2026–2032. Their growing importance reflects the increasing need for specialized neuromuscular care, early diagnosis, and coordinated treatment of progressive muscle weakness. Specialty clinics provide multidisciplinary services involving neurologists, physiotherapists, and rehabilitation specialists, alongside access to clinical trials and emerging therapeutic interventions, strengthening their role in long-term IBM management and personalized patient care. By Geography: North America Leads as Asia-Pacific Expands Diagnostic Access Leading Region – North America North America dominated the global Inclusion Body Myositis (IBM) Market, accounting for the largest 42% market share, valued at approximately USD 189.10 million in 2025, with a projected CAGR of 4.51% during 2026–2032. Growing clinical recognition, advancements in diagnostic standards, and expanding research initiatives are strengthening the region’s position in IBM diagnosis and management. Increasing adoption of muscle biopsy, specialized neurological assessments, and clinical monitoring reflects the transition of IBM from a historically underrecognized muscle disorder into an increasingly researched rare neuromuscular disease. Fastest-Growing Region – Asia-Pacific Asia-Pacific Inclusion Body Myositis (IBM) Market accounted for 20% of global market share, equivalent to USD 90.05 million in 2025, and is projected to expand at the fastest regional CAGR of 7.40% during 2026–2032. Increasing aging populations across Japan, China, South Korea, and Australia are accelerating clinical recognition of IBM and encouraging earlier diagnosis. Expanding neuromuscular specialty care, improved access to muscle biopsy procedures, and growing participation in rare disease research are strengthening treatment accessibility and clinical management across the region. Which Emerging Therapies and Clinical Pipeline Innovations Are Reshaping the Treatment Landscape for Inclusion Body Myositis? Ulviprubart (ABC008) – KLRG1-Targeted Immunotherapy: Abcuro is developing ulviprubart, a monoclonal antibody designed to selectively eliminate KLRG1-positive cytotoxic T cells associated with muscle damage. Its Phase II/III MUSCLE trial enrolled 272 patients but did not achieve its primary endpoint. However, patients with less severe disease demonstrated approximately 50% slower functional decline versus placebo in a prespecified subgroup analysis. In August 2026, Abcuro secured USD 66 million to support a new potentially registrational Phase III study focused on this population, with initiation planned for the fourth quarter of 2026. Sirolimus (Rapamycin) – mTOR Inhibition and Autophagy Regulation: Sirolimus targets the mTOR signaling pathway, potentially improving cellular protein clearance while regulating inflammatory immune responses. The international Phase IIb/III OPTIMISM study is evaluating 140 IBM patients, comparing oral sirolimus with placebo. Its commercial relevance lies in the possibility of repurposing an established medicine for disease modification, contingent on demonstrating meaningful functional benefits. Brepocitinib – TYK2/JAK1 Pathway Inhibition: Developed by Priovant Therapeutics, brepocitinib is an oral inhibitor of inflammatory cytokine signaling. Its clinical development in dermatomyositis provides evidence relevant to inflammatory muscle diseases, although IBM-specific therapeutic efficacy remains unestablished. Its potential relevance to IBM lies in the broader investigation of cytokine-driven muscle inflammation. Anifrolumab (Saphnelo) – Type I Interferon Receptor Blockade: AstraZeneca's anifrolumab targets the type I interferon receptor to suppress inflammatory signaling. Its Phase III JASMINE study plans to evaluate 240 patients with dermatomyositis or polymyositis. The mechanism offers a research direction for inflammatory myopathies, although the study does not directly evaluate IBM. Next-Generation Targeted Immunotherapies: Research into cytotoxic CD8-positive T cells, KLRG1 expression, and impaired cellular protein clearance is supporting more selective therapeutic strategies. These approaches aim to address the inflammatory and degenerative components of IBM simultaneously, creating longer-term opportunities for precision medicines and biomarker-guided patient selection. Which Companies Are Advancing Targeted Therapeutics and Clinical Innovation in the Inclusion Body Myositis Market? Abcuro, Inc. Abcuro, Inc. is among the most prominent IBM-focused biotechnology developers, advancing ulviprubart (ABC008), a monoclonal antibody designed to selectively eliminate KLRG1-positive cytotoxic T cells implicated in muscle damage. Its Phase II/III MUSCLE trial enrolled 272 patients and evaluated functional outcomes over 76 weeks. Although the overall study did not achieve its primary endpoint, a prespecified subgroup of patients with less severe disease demonstrated approximately 50% slower functional deterioration versus placebo, without reaching statistical significance. In August 2026, Abcuro secured USD 66 million in Series D financing to support another potentially registrational Phase III trial targeting patients with less advanced IBM. The company planned to initiate the study in the fourth quarter of 2026. This targeted development strategy positions Abcuro as an important participant in the potential introduction of disease-modifying IBM therapies, with future commercial opportunities dependent on confirmatory clinical results and regulatory approval. Other Companies and Their Roles: Novartis AG: Previously investigated bimagrumab, an activin type II receptor-targeting antibody, in a 251-patient IBM trial, contributing clinical evidence on muscle mass and functional outcomes despite the study missing its primary endpoint. Zevra Therapeutics: Develops arimoclomol for Niemann-Pick disease type C; the compound was previously evaluated in a 152-patient IBM trial under Orphazyme, without demonstrating significant functional improvement. BioMarin Pharmaceutical Inc.: Specializes in genetic and rare-disease therapeutics, providing adjacent pharmaceutical expertise, although a direct IBM-specific therapeutic program has not been established in its disclosed pipeline. Pfizer Inc.: Investigates PF-06823859 for dermatomyositis and polymyositis, contributing to the broader inflammatory myopathy therapeutic landscape; its trial specifically excludes IBM patients. Analyst Commentary: How Will Patient Selection and Functional Benefits Shape Therapeutic Investment? The Inclusion Body Myositis Market presents a significant opportunity for precision immunotherapies capable of slowing muscle deterioration and preserving functional independence. Future therapeutic success will increasingly depend on identifying responsive patient populations, integrating disease-specific biomarkers, and demonstrating measurable improvements in mobility and muscle strength. Targeted immune-cell modulation, autophagy-based treatments, and earlier clinical intervention represent promising directions for pharmaceutical innovation. The greatest commercial potential lies in clinically validated disease-modifying therapies that can achieve regulatory approval, reimbursement acceptance, and sustained adoption in specialized neuromuscular care. Inclusion Body Myositis Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 450.23 Million Revenue Forecast in 2032 USD 649.13 Million Overall Growth Rate CAGR of 5.4% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Treatment Type, By Diagnosis, By Patient Age Group, By Route of Administration, By End User, By Geography By Treatment Type Supportive Care, Physical Therapy, IVIG Therapy, Immunosuppressive Therapy, Investigational Therapies By Diagnosis Muscle Biopsy, Electromyography (EMG), Blood Tests, Magnetic Resonance Imaging (MRI) By Patient Age Group Below 50 Years, 50–64 Years, 65 Years and Above By Route of Administration Oral Administration, Intravenous Administration, Subcutaneous Administration By End User Hospitals, Specialty Clinics, Rehabilitation Centers, Home Healthcare By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Improved disease recognition and diagnostic access, expanding specialized neuromuscular care, long-term rehabilitation and mobility support requirements, aging patient populations, clinical development of disease-modifying therapies Customization Option Available upon request Frequently Asked Question About This Report Q1. Why does supportive care account for the largest treatment share in the market? A1. Progressive weakness creates continuing requirements for mobility assistance, rehabilitation and swallowing support. Conventional medicines have limited effectiveness in slowing progression. Supportive care therefore leads the treatment category with an estimated 35% share in 2025, reflecting ongoing spending on maintaining independence and daily function. Q2. What clinical development challenges are affecting the industry? A2. Developers must demonstrate meaningful preservation of function in a slowly progressing disease. Several trials have missed their primary endpoints. Encouraging subgroup findings require confirmation before they can establish a treatment’s effectiveness or support a dependable commercial opportunity. Q3. How could earlier diagnosis influence market development? A3. Earlier identification can connect patients with specialist care and appropriate supportive services sooner. The report cites a U.S. study in which symptoms preceded diagnosis by an average of 4.4 years. Shortening that delay could also improve identification of eligible clinical trial participants. Q4. Which healthcare settings offer expanding opportunities in the market? A4. Specialty clinics are projected to grow fastest among end users at a CAGR of 6.50% during 2026–2032. Their role combines neuromuscular assessment with coordinated rehabilitation and long-term monitoring. Hospitals remain the largest setting with an estimated 44% share in 2025. Q5. What factors will determine future investment opportunities in the industry? A5. The strongest opportunity lies in therapies that demonstrate sustained benefits in mobility and daily function. Developers also need to identify patients most likely to respond. Regulatory approval and reimbursement acceptance will determine whether clinical progress translates into routine prescribing and commercial revenue. Sources: U.S. National Library of Medicine – Lists the Phase III Sirolimus OPTIMISM Trial With an Estimated Enrollment of 140 IBM Patients and Functional Assessment Over 84 Weeks ClinicalTrials.gov – Sirolimus in Inclusion Body Myositis: NCT04789070 U.S. National Library of Medicine – Records 251 Participants in Novartis’ Completed Bimagrumab IBM Trial, Which Evaluated Changes in Six-Minute Walking Distance at Week 52 ClinicalTrials.gov – Bimagrumab in Sporadic Inclusion Body Myositis: NCT01925209 U.S. National Library of Medicine – Records 152 Participants in the Completed Arimoclomol IBM Trial, With Functional Outcomes Evaluated Over 20 Months ClinicalTrials.gov – Arimoclomol in Inclusion Body Myositis: NCT02753530 U.S. FDA – Granted Orphan Drug Designation to Abcuro’s KLRG1-Targeting Antibody for IBM on July 7, 2020; Its Database Lists the Orphan Indication as Not FDA Approved FDA – Abcuro KLRG1 Antibody: IBM Orphan Designation and Approval Status European Medicines Agency – Reports That Ulviprubart Received EU Orphan Designation for IBM on July 25, 2023, Under Designation Number EU/3/23/2805 EMA – Ulviprubart: Orphan Designation for Inclusion Body Myositis Abcuro-Sponsored Research – Estimated Diagnosed U.S. IBM Prevalence at 26.45 Patients per Million Using Claims Data and the 2023 U.S. Census Population Abcuro – AAN 2025 Poster: IBM Epidemiology and Diagnosed Patient Prevalence Abcuro-Sponsored Research – Analyzed 2,435 IBM Patients, Finding That 71% Were Aged 65 or Older at Diagnosis and the Median Interval From First Recorded Symptom to Diagnosis Was 4.4 Years Abcuro – IBM Patient Demographics and Diagnostic Delay Analysis Abcuro-Sponsored Research – Found That 30% of IBM Patients Had Emergency Department Visits, 62% Had Outpatient Hospital Visits, and 84% Had Outpatient Office Visits During the Year Before Diagnosis Abcuro – Healthcare Resource Utilization Among 2,435 IBM Patients Quest Diagnostics – Documents Its cN-1A Antibody Test, Code 10266, as an Aid to IBM Diagnosis and Differentiation From Other Muscle Diseases Quest Diagnostics – cN-1A Antibody Testing for Inclusion Body Myositis EUROIMMUN – Supplies an Anti-cN-1A ELISA and a 20-Antigen Myositis Profile Including cN-1A; Its Brochure Reports ELISA Specificity Above 96% and Sensitivity Up to 39% EUROIMMUN – IBM-Related Antibody Tests and Diagnostic Performance Information Abcuro – Evaluated Subcutaneous Ulviprubart Administration Every Eight Weeks Over Approximately 76 Weeks in Its Completed Phase II/III IBM Study Abcuro – IBM Clinical Studies: Administration Route, Schedule, and Development Status Table of Contents - Global Inclusion Body Myositis Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Treatment Type, Diagnosis, Patient Age Group, Route of Administration, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Treatment Type, Diagnosis, Patient Age Group, Route of Administration, End User, and Geography Precision Immunotherapies, Clinical Pipelines, and Specialized Neuromuscular Care Market Share Analysis Leading Players and Competitive Market Positioning Market Share Analysis by Treatment Type Market Share Analysis by Diagnosis Market Share Analysis by Patient Age Group Market Share Analysis by Route of Administration Market Share Analysis by End User Regional Market Share Analysis Investment Opportunities in the Inclusion Body Myositis Market Key Developments and Innovations in IBM Treatment Clinical Pipeline Advancements and Therapeutic Development Investment Opportunities in Investigational Therapies Targeted Immunotherapies and KLRG1-Targeted Treatment Research Opportunities in Muscle Biomarkers and Anti-cN1A Antibody Testing Advancements in Muscle Biopsy, Electromyography, Blood Tests, and MRI Physical Therapy, Occupational Therapy, Mobility Assistance, and Swallowing Rehabilitation Clinical Trial Development, Patient Selection, and Personalized Neuromuscular Care Market Introduction Definition and Scope of the Study Overview of Inclusion Body Myositis and Its Clinical Characteristics Market Structure and Key Findings Overview of Top Investment Pockets Progressive Muscle Weakness, Mobility Limitations, and Swallowing Complications Importance of Neurological Consultations, Muscle Biopsies, Diagnostic Testing, and Rehabilitation Long-Term Disease Management and Supportive Care Requirements Role of Precision Immunotherapy and Disease-Modifying Treatment Research Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Historical Market Assessment (2019–2024) Base Year Assessment (2025) Market Forecasting Methodology (2026–2032) Market Dynamics Key Market Drivers Challenges and Restraints Impacting Market Growth Emerging Opportunities for Stakeholders Impact of Clinical Research and Regulatory Factors Role of Supportive Care, Physical Therapy, and Rehabilitation in IBM Management Increasing Need for Earlier Diagnosis and Specialized Neuromuscular Care Potential of Investigational Therapies and Targeted Immunotherapies Clinical Trial Outcomes, Patient Selection, and Functional Endpoint Assessment Long-Term Mobility Assistance and Swallowing Intervention Requirements Global Inclusion Body Myositis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type: Supportive Care Physical Therapy IVIG Therapy Immunosuppressive Therapy Investigational Therapies Market Analysis by Diagnosis: Muscle Biopsy Electromyography (EMG) Blood Tests Magnetic Resonance Imaging (MRI) Market Analysis by Patient Age Group: Below 50 Years 50–64 Years 65 Years and Above Market Analysis by Route of Administration: Oral Administration Intravenous Administration Subcutaneous Administration Market Analysis by End User: Hospitals Specialty Clinics Rehabilitation Centers Home Healthcare Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Inclusion Body Myositis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Diagnosis, Patient Age Group, Route of Administration, and End User IBM Diagnosis, Neuromuscular Specialist Access, and Clinical Research Supportive Care, Rehabilitation, and Investigational Therapy Development Country-Level Breakdown: United States Canada Europe Inclusion Body Myositis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Diagnosis, Patient Age Group, Route of Administration, and End User Neuromuscular Diagnostic Services and Specialized Patient Management Clinical Trial Participation and Emerging Therapeutic Research Country-Level Breakdown: Germany United Kingdom France Italy Rest of Europe Asia-Pacific Inclusion Body Myositis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Diagnosis, Patient Age Group, Route of Administration, and End User Neurological Diagnostic Access and Specialized Healthcare Infrastructure Muscle Biopsy, MRI, Rehabilitation, and Long-Term Neuromuscular Care Country-Level Breakdown: China Japan South Korea India Australia Rest of Asia-Pacific Latin America Inclusion Body Myositis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Diagnosis, Patient Age Group, Route of Administration, and End User Neuromuscular Disease Recognition and Access to Diagnostic Services Rehabilitation Services and Long-Term Supportive Care Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa Inclusion Body Myositis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Diagnosis, Patient Age Group, Route of Administration, and End User Specialized Neurological Care and Diagnostic Availability Access to Rehabilitation, Mobility Assistance, and Long-Term Patient Support Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players and Related Companies: Abcuro, Inc. Novartis AG Zevra Therapeutics BioMarin Pharmaceutical Inc. Pfizer Inc. Priovant Therapeutics AstraZeneca Roche Johnson & Johnson Competitive Landscape and Strategic Insights Company Research and Development Strategies Benchmarking Based on Clinical Pipeline Progress, Therapeutic Mechanisms, and Patient Selection Targeted Immunotherapy and Disease-Modifying Treatment Development Investigational Drug Development and Clinical Trial Outcomes Specialized Neuromuscular Care and Supportive Treatment Positioning Distinction Between IBM-Specific Clinical Evidence and Research in Other Inflammatory Myopathies Appendix Abbreviations and Terminologies Used in the Report References and Sources Clinical Trial and Investigational Therapy References Market Definitions and Segment Classification Historical Data Coverage (2019–2024) Base Year Definitions and Assumptions (2025) Forecast Methodology and Assumptions (2026–2032) Country and Regional Coverage List of Tables Market Segmentation by Treatment Type, Diagnosis, Patient Age Group, Route of Administration, End User, and Region (2026–2032) Historical Market Size and Volume (2019–2024), Base Year Market Size Analysis (2025), and Market Forecasts (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Country-Level Market Coverage Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Supportive Care and Physical Therapy Market Analysis Diagnostic Segment Analysis: Muscle Biopsy, EMG, Blood Tests, and MRI Patient Age Group and End User Market Analysis Route of Administration: Oral, Intravenous, and Subcutaneous Investigational Therapies and Clinical Pipeline Overview Competitive Benchmarking of Leading and Related Companies Clinical Trial Overview: MUSCLE, OPTIMISM, JASMINE, and Other Relevant Research Programs List of Figures Market Drivers, Challenges, Opportunities, and Restraints Global Inclusion Body Myositis Market Structure Regional Market Snapshot Across All Covered Regions Market Share by Treatment Type, Diagnosis, Patient Age Group, Route of Administration, and End User (2025 vs. 2032) Competitive Landscape and Clinical Pipeline Positioning Targeted Immunotherapy and Disease-Modifying Treatment Research IBM Diagnostic Pathways and Long-Term Neuromuscular Care Global Inclusion Body Myositis Ecosystem and Value Chain Analysis Market Trends Across Historical Data (2019–2024), Base Year (2025), and Forecast Period (2026–2032)